Immune-Onc Therapeutics Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Employees
  • 14
Employees
  • Latest Deal Type
  • Series B1
  • Latest Deal Amount
  • $72.9M
Latest Deal Amount
  • Investors
  • 16

Immune-Onc Therapeutics General Information

Description

Developer of cancer biotherapeutics designed to revolutionize the treatment for people with cancers. The company's biotherapeutics are antibodies that target the immune inhibitory receptor and navigates immune suppression and tumor infiltration, enabling patients to have access to new immunomodulatory approaches.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 795 San Antonio Road
  • Palo Alto, CA 94303
  • United States

Immune-Onc Therapeutics Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Immune-Onc Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series B1) 30-Mar-2021 $72.9M 00000 00000 Completed Clinical Trials - General
5. Grant 04-Aug-2020 00.000 0000 Completed Pre-Clinical Trials
4. Debt - PPP 13-Apr-2020 0000 Completed Pre-Clinical Trials
3. Early Stage VC (Series B) 18-Sep-2018 0000 0000 0000 Completed Pre-Clinical Trials
2. Accelerator/Incubator 28-Jun-2017 $7M Completed Product Development
1. Early Stage VC (Series A) 01-Sep-2016 $7M $7M 0000 Completed Product Development
To view Immune-Onc Therapeutics’s complete valuation and funding history, request access »

Immune-Onc Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B2 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.00
Series B1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 20,988,105 $0.000100 6% $1.58 $1.58 1x $1.58 20.77%
Series A 8,634,934 $0.000100 6% $0.81 $0.81 1x $0.81 8.55%
To view Immune-Onc Therapeutics’s complete cap table history, request access »

Immune-Onc Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of cancer biotherapeutics designed to revolutionize the treatment for people with cancers. The company's bioth
Drug Discovery
Palo Alto, CA
14 As of 2021
00000
0000 0000-00-00
00000000000 00000

00000 00

r sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna
0000 000000000
Geneva, Switzerland
00 As of 0000
00000
0000000000 0 00000

00000000

s nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
0000 000000000
Exton, PA
000 As of 0000
0000
0000 0000-00-00
000000&0 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Immune-Onc Therapeutics Competitors (51)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Light Chain Bioscience Venture Capital-Backed Geneva, Switzerland 00 00000 0000000000 0 00000
000000000 Formerly VC-backed Exton, PA 000 0000 000000&0 0000
000000000 00000000 Venture Capital-Backed Rockville, MD 0 000.00 0000000000 0 000.00
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
000000000000000 Venture Capital-Backed Saint Louis, MO 0 000.00 00000000000 000.00
You’re viewing 5 of 51 competitors. Get the full list »

Immune-Onc Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
Charlene Liao Ph.D Co-Founder, President, Chief Executive Officer & Board Member
An Song Ph.D Chief Scientific Officer
Guo-Liang Yu Ph.D Board Member & Co-Founder
Ji Li Ph.D Vice President of Business Development, Finance & Operations and Chief of Staff
Paul Woodard MD Chief Medical Officer
You’re viewing 5 of 6 executive team members. Get the full list »

Immune-Onc Therapeutics Board Members (7)

Name Representing Role Since
Bing Yao Immune-Onc Therapeutics Board Member 000 0000
Charlene Liao Ph.D Immune-Onc Therapeutics Co-Founder, President, Chief Executive Officer & Board Member 000 0000
Dave Chenn Oceanpine Capital Board Member 000 0000
Feng Deng Northern Light Venture Capital Board Member 000 0000
Guo-Liang Yu Ph.D Immune-Onc Therapeutics Board Member & Co-Founder 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Immune-Onc Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immune-Onc Therapeutics Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Oceanpine Capital Venture Capital Minority 000 0000 000000 0
Octagon Capital Investments Other Minority 000 0000 000000 0
Sphera Funds Management Hedge Fund Minority 000 0000 000000 0
The Leukemia & Lymphoma Society Corporation Minority 000 0000 000000 0
National Cancer Institute Government 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »